Skip to main content
NCBI home page
Journal of Cancer Research and Clinical Oncology logoLink to Journal of Cancer Research and Clinical Oncology
. 1985 Sep;110(2):115–118. doi: 10.1007/BF00402722

6-Thioguanine: High-dose 2-H infusions in goats

Teunis J Schouten 1,✉, Ronney A De Abreu 1, Egbert D A M Schretlen 1, Marinella B van Leeuwen 1, John M van Baal 1, Gérard A M de Vaan 1
PMCID: PMC12253155  PMID: 4044625

Abstract

6-Thioguanine (6TG) is poorly absorbed after oral administration. Bolus injections of 6TG result in high peak concentrations with relatively shortlived plasma concentrations. In vitro studies have shown the importance of prolonged exposure to 6TG. Therefore we administered 6TG by infusion at a dose rate of 2 mg/h over 2 h. In three goats we determined the plasma concentration-time curves of 6TG and its riboside (6TGR).

A steady state was reached for 6TG and was almost reached for 6TGR within the 2 h of infusion. In one experiment we obtained several samples of CSF and observed good penetration of 6TG and 6TGR into CSF. Urinary excretion of 6TG and 6TGR was also quantitated. The amount of drug and metabolite excreted later than 4 h after the end of the infusion was negligible. By infusing 6TG, the problems of both erratic absorption after oral administration and acute renal toxicity after bolus injection, can be averted. In our opinion prolonged infusions of 6TG may be of advantage in humans suffering from actively proliferating malignant diseases, and thus should be studied.

Key words: 6-Thioguanine, 6-Thioguanosine, 6-Thioguanine riboside, 6-Mercaptopurine, Thiopurines

Footnotes

Supported by the “Queen Wilhelmina Fund” (Dutch Cancer Society); Grant NUKC KG 81-2

References

  1. Baal JM van, Leeuwen MB van, Schouten TJ, Abreu RA De (1984) Sensitive high-performance liquid chromatographic determination of 6-mercaptopurine, 6-thioguanine, 6-mercaptopurine riboside and 6-thioguanosine in biological fluids. J Chromatogr 336:422–428 [DOI] [PubMed] [Google Scholar]
  2. Britell JC, Moertel CG, Kvols LK, O'Connell MJ, Rubin J, Schutt AJ (1981) Phase II trial and IV 6-thioguanine in advanced colorectal carcinoma. Cancer Treat Rep 65:909–910 [PubMed] [Google Scholar]
  3. Brox LW, Birkett L, Belch A (1981) Clinical pharmacology of oral thioguanine in acute myclogenous leukemia. Cancer Chemother Pharmacol 6:35–38 [DOI] [PubMed] [Google Scholar]
  4. Ding TL, Benet LZ (1979) Comparative bioavailability and pharmacokinetic studies of azathioprine and 6-mercaptopurine in the Rhesus monkey. Drug Metab Dispos 7:373–377 [PubMed] [Google Scholar]
  5. Konits PH, Egorin MJ, Van Echo DA, Aisner J, Andrews PA, May ME, Bachur NR, Wiernik PH (1982) Phase II evaluation and plasma pharmacokinetics of high-dose intravenous 6-thioguanine in patients with colorectal carcinoma. Cancer Chemother Pharmacol 8:199–203 [DOI] [PubMed] [Google Scholar]
  6. Karkoff IH, Ellison RR, Tan CTC (1961) Clinical evaluation of thioguanosine. Cancer Res 21:1015–1019 [PubMed] [Google Scholar]
  7. Lee SH, Sartorelli AC (1981) The effects of inhibitors of DNA biosynthesis on the cytotoxicity of 6-thioguanine. Cancer Biochem Biophys 5:189–194 [PubMed] [Google Scholar]
  8. LePage GA, Whitecar JP (1971) Pharmacology of 6-thioguanine in man. Cancer Res 31:1627–1631 [PubMed] [Google Scholar]
  9. Lilleyman JS, Lennard L, Rees CA, Morgan G, Maddocks JL (1984) Childhood lymphoblastic leukaemia: Sex difference in 6-mercaptopurine utilization. Br J Cancer 49:703–707 [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Loo TK, Lu K, Benvenuto JA, Rosenblum MG (1981) Disposition and metabolism of thiopurines III. β-2′-Deoxythioguanosine and 6-thioguanine in the dog. Cancer Chemother Pharmacol 6:131–136 [DOI] [PubMed] [Google Scholar]
  11. Lu K, Benvenuto JA, Bodey GP, Gottlieb JA, Rosenblum MG, Loo TL (1982) Pharmacokinetics and metabolism of β-2′-deoxythioguanosine and 6-thioguanine in man. Cancer Chemother Pharmacol 8:119–123 [DOI] [PubMed] [Google Scholar]
  12. Mellett LB (1977) Physicochemical considerations and pharmakokinetic behavior in delivery of drugs to the central nervous system. Cancer Treat Rep 61:527–531 [PubMed] [Google Scholar]
  13. Nelson JA, Carpenter JW, Rose LM, Adamson DJ (1975) Mechanisms of action of 6-thioguanine, 6-mercaptopurine, and 8-azaguanine. Cancer Res 35:2872–2878 [PubMed] [Google Scholar]
  14. Paterson ARP, Tidd, DM (1975) 6-Thiopurines. In: Sartorelli AC, Johns DG (eds). Antineoplastic and immunosuppressive agents. Springer, Berlin Heidelberg New York, Part II: 384–403 (Handbook of Experimental Pharmacology 38/2) [Google Scholar]
  15. Schouten TJ, Abreu RA De, Bruyn CHMM de, Kleijn E van der, Oosterbaan MJM, Schretlen EDAM, Vaan GAM de (1984) 6-Mercaptopurine: pharmacokinetics in animals and preliminary results in children. Adv Exp Med Biol 165B:367–370 [DOI] [PubMed] [Google Scholar]
  16. Schouten TJ, Abreu RA De, Schretlen EDAM, Bruyn CHMM de, Kleijn E van der, Oosterbaan MJM, Vaan GAM de (1985a) 6-Mercaptopurine: oral administration and i.v. bolus injections in dogs. Eur Paediatr Haematol Oncol 1985 (in press)
  17. Schouten TJ, Abreu RA De, Schretlen EDAM, Vaan GAM de, Kleijn E van der (1985b) 6-Mercaptopurine: total body autoradiograms und plasma concentration-time curves of 6MP and metabolites form Marmoset monkeys. Eur Paediatr Haematol Oncol (in press) [DOI] [PubMed]
  18. Schouten TJ, Abreu RA De, Schretlen EDAM, Baal JM van, Leeuwen MB van, Vaan GAM de (1985c) 6-Mercaptopurine: High-dose 24 hours infusions in goats. (submitted)
  19. Tidd DM, Paterson ARP (1974) A biochemical mechanism for the delayed cytotoxic reaction of 6-mercaptopurine. Cancer Res. 34:738–746 [PubMed] [Google Scholar]
  20. Wotring LL, Roti Roti JL (1980) Thioguanine-induced S and G2 blocks and their significance to the mechanism of cytotoxicity. Cancer Res 40:1458–1462 [PubMed] [Google Scholar]
  21. Zimm S, Collins JM, Riccardi R, O'Neill D, Narang PK, Chabner BA, Poplack DG (1983a) Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? N Engl J Med 308:1005–1009 [DOI] [PubMed] [Google Scholar]
  22. Zimm S, Collins JM, O'Neill D, Chabner BA, Poplack DG (1983b) Inhibition of first-pass metabolism in cancer chemotherapy:interaction of 6-mercaptopurine and allopurinol. Clin Pharmacol Ther 34:810–817 [DOI] [PubMed] [Google Scholar]
  23. Zimm S, Ettinger L, Holcenberg J, Kamen B, Vietti T, Balis F, Collins J, Poplack DG (1984) 6-Mercaptopurine administered as a prolonged intravenous (IV) infusion: plasma and CSF pharmacokinetics. Proc Am Soc Clin Oncol 3:37 (C-143) [Google Scholar]

Articles from Journal of Cancer Research and Clinical Oncology are provided here courtesy of Springer

RESOURCES